Millions of Americans are making a decision that a sweeping new body of research now shows is increasingly temporary: stopping their GLP-1 medication.
A study reported by ScienceDaily on June 16–17, 2026 — based on research presented at ENDO 2026, the Endocrine Society's annual meeting in Chicago — analyzed Komodo Health U.S. claims data from January 2019 to June 2025, covering adults ages 18 to 64 with type 2 diabetes and a BMI of 25 kg/m² or higher who had started on liraglutide (Victoza), semaglutide (Ozempic), or tirzepatide (Mounjaro). The lead author, Sainikhil Sontha, M.S., a research associate at Boston University School of Public Health, explained the two core questions: "How many people with type 2 diabetes taking GLP-1 medications actually stop using them? And how many restart them?"
